Hemodynamic Measurements of Macrocirculatory and Perfusion Parameters in ICU

Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Jan 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called norepinephrine (NE) affects blood circulation in patients experiencing septic shock, a serious condition caused by infection that leads to low blood pressure and poor blood flow. The researchers want to understand the relationship between the larger blood vessels (macrocirculation) and the smaller blood vessels (microcirculation) in order to improve how doctors manage fluids and medications for patients in the Intensive Care Unit (ICU). By closely monitoring these effects, the study aims to provide better, personalized treatments for individuals suffering from septic shock.

To participate in the trial, patients must be adults aged 65 or older who have a suspected or confirmed infection and require medication to keep their blood pressure at a safe level. They should also have certain lab results indicating a need for treatment, specifically a high level of lactate in their blood. Patients with specific heart conditions or those receiving certain other treatments may not be eligible. If someone joins the study, they can expect to have their circulation closely monitored and receive targeted care aimed at improving their condition. This research is important because it seeks to enhance our understanding of how to better support patients in critical situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Suspected or documented infection
• • Need for vasopressors to maintain mean arterial blood pressure (MAP) ≥65 mmHg
• • Serum lactate levels \>2 mmol/L
• • Norepinephrine infusion of \> 0.2 mcg/kg/min
• Exclusion Criteria:
• • Absolute contraindication for esophageal doppler or urinary catheter insertion as noted in the patients' charts.
• • Severe valvular pathology and cardiac arrhythmias resulting in severe hemodynamic instability.
• • Lithium treatment
• • Treatment with other vasopressor or inotropic drugs.